Pralsetinib, another selective RET inhibitor, has been approved exclusively by the FDA in 2020 for advanced RET-mutant MTC patients, based on the beneficial outcomes observed in the ARROW study, and no further development in TC is expected [76]. This evidence concerns the gene RET and medullary thyroid gland carcinoma.